
HOME		SEARCH		RSS FEED		SUBSCRIBE

Search Results - cb7xxx

5 Results

Sort By:

Highly Potent and Selective Deubiquitinating Enzyme Inhibitor

Available for licensing are inhibitors that target the USP1/ UAF1 deubiquitinating enzyme (DUB) complex. The FDA approval and commercial success of Velcade®, a small molecule proteasome inhibitor, has established the ubiquitin-proteasome system (UPS) as a valid target for anticancer treatment. However, proteasome inhibitors in general suffer from...

Published: 7/29/2024 | Inventor(s): Andrew Rosenthal, Ajit Jadhav, Thomas Dexheimer, Anton Simeonov, Qin Liang, Zhihao Zhuang, David Maloney

Keywords(s): CANCER, CANCER THERAPEUTICS, CB5XXX, CB7XXX, CBXXXX, Combination Therapy, CXXXXX, Deubiquitinase, Inhibitors, POTENT, protease inhibitors, SELECTIVE, small molecule, USP1/UAF1

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics

Small-Molecule Inhibitors of Human Galactokinase for the Treatment of Galactosemia and Cancers

Lactose, found in dairy products and other foods, is comprised of two simple sugars, glucose and galactose. In galactosemia, where galactose is not properly metabolized, build-up of toxic compounds, such as galactose-1-phosphate, can lead to liver disease, renal failure, cataracts, brain damage, and even death if this disorder is left untreated. Currently,...

Published: 7/25/2024 | Inventor(s): Matthew Boxer

Keywords(s): AKT, CANCER, CB7XXX, CBXXXX, CXXXXX, Galactokinase, Galactose, Galactosemia, IBXXXX, Inhibitors, IXXXXX, lactose, Metabolism, PTEN, rare disease, small molecule, UAXXXX

Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Oncology, Application > Diagnostics, TherapeuticArea > Rare / Neglected Diseases, Application > Research Materials

Metallic Nanoparticles for Photothermal Therapy

The invention relates to the preparation and application of 20-150nm metallic nanoparticulate vesicles for photothermal anti-cancer therapy. The vesicles comprise metallic nanoparticles covalently bound to a hydrophilic and hydrophobic polymer. The preparation method generally entails dispersing a polymer-bound metallic nanoparticle in an organic...

Published: 7/25/2024 | Inventor(s): Jibin Song, Xiaoyuan (Shawn) Chen

Keywords(s): CB7XXX, Nanoparticle, Nanoparticle-Based, Nanoparticles, Nanoparticulate, phototherapy, Photothermal, Photothermal/Photodynamic, PXXXXX, XGXXXX, YBXXXX

Category(s): Collaboration Sought > Collaboration, Application > Research Materials, Application > Diagnostics, Application > Therapeutics, Application > Consumer Products, TherapeuticArea > Oncology

Anti-Proliferative Activity of an Unexpected mTOR Kinase Inhibitor

The second leading cause of death in the United States is cancer and more than one million Americans are diagnosed with cancer each year, with this number likely to increase as the population ages. There remains a need for effective therapeutics with improved safety profiles, and promising results have been obtained from targeting the phosphatidylinositol-3-kinase...

Published: 4/8/2024 | Inventor(s): Joel Moss, Arnold Kristof

Keywords(s): BBXXXX, CB7XXX, CBXXXX, CXXXXX, IB3XXX, IBXXXX, IXXXXX

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Research Materials, Application > Therapeutics, Application > Diagnostics, TherapeuticArea > Immunology, TherapeuticArea > Oncology

Vitamin D Receptor Antagonists for Treating Breast Cancer

Vitamin D receptor (VDR) is a nuclear receptor that is activated by calcitriol, the active form of vitamin D. It is best known for regulating dietary calcium uptake necessary for bone growth, but it also affects cell proliferation and differentiation. Therefore, it was thought that treatment with calcitriol or its derivatives could be useful to treat...

Published: 4/8/2024 | Inventor(s): Julianna Barsony

Keywords(s): ANTAGONISTS, ANTICANCER, CB7XXX, CBXXXX, CXXXXX, D, EFFECTS, Glioma, Novel, RECEPTOR, Vitamin

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology

|

|

|

© 2024. All Rights Reserved. Powered by Inteum